Literature DB >> 10644648

Interleukin-1beta deficiency results in reduced NF-kappaB levels in pregnant mice.

L L Reznikov1, B D Shames, H A Barton, C H Selzman, G Fantuzzi, S H Kim, S M Johnson, C A Dinarello.   

Abstract

Interleukin (IL)-1beta-deficient (IL-1beta(-/-)) mice were assessed for cytokine production during pregnancy. A significant reduction in nuclear factor (NF)-kappaB p65 protein content was observed in the uteri and spleens of pregnant IL-1beta(-/-) mice, as demonstrated by immunohistochemistry and Western immunoblot analysis. In addition, electromobility gel shift assay revealed less DNA binding activity of NF-kappaB p65-containing complex in pregnant IL-1beta(-/-) mice. To investigate differences in cytokine production regulated by NF-kappaB, the levels of tumor necrosis factor-alpha, macrophage inflammatory protein-1alpha, and interferon-gamma were measured in the uterine wall, spleen homogenates, and spleen cell cultures obtained from pregnant mice. Endocervical administration of lipopolysaccharide (LPS) increased cytokine levels in both wild-type (IL-1beta(+/+)) and IL-1beta(-/-) animals, but in IL-1beta(-/-) mice this response was 50-75% lower. Splenocytes from nonpregnant mice exhibited decreased LPS-induced cytokine production when primed in vitro with progesterone. This suppression was 25% greater in IL-1beta(-/-) than in IL-1beta(+/+) mice. These data suggest that constitutive NF-kappaB p65 protein synthesis is regulated by IL-1beta, particularly during pregnancy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10644648     DOI: 10.1152/ajpregu.2000.278.1.R263

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  1 in total

1.  Modulation of monocyte chemotactic protein-1 expression during lipopolysaccharide-induced preterm delivery in the pregnant mouse.

Authors:  Allaire K Diamond; Leigh M Sweet; Karen H Oppenheimer; Diana F Bradley; Mark Phillippe
Journal:  Reprod Sci       Date:  2007-09       Impact factor: 3.060

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.